CC
TARS icon

Centiva Capital’s Tarsus Pharmaceuticals TARS Stock Holding History

Centiva Capital’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,959
Closed -$219K – 2118
2024
Q4 		$219K Buy
+3,959
New +$180K ﹤0.01% 1324

Other funds holding TARS

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Centiva Capital's TARS Position: Q1 2025 in Review

Centiva Capital sold out of Tarsus Pharmaceuticals (TARS) in Q1 2025, closing a stake of 3,959 shares — an estimated $219K sold.

Centiva Capital first reported a position in TARS in Q4 2024 and held it in 1 quarter. The position peaked at $219K in Q4 2024. 194 funds tracked by Wall St. Rank hold TARS as of Q1 2025.

  • Centiva Capital reported no remaining Tarsus Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Centiva Capital sold 3,959 Tarsus Pharmaceuticals shares in Q1 2025, an estimated $219K.
  • Centiva Capital first reported a position in Tarsus Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Centiva Capital's Tarsus Pharmaceuticals position peaked at $219K in Q4 2024.
  • 194 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2025.

Based on Centiva Capital's 13F filing for Q1 2025, filed 15 May 2025.